TherapeuticsMD’s (TXMD) “Buy” Rating Reiterated at Noble Financial

TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating restated by research analysts at Noble Financial in a research report issued to clients and investors on Friday, December 29th.

TXMD has been the topic of several other reports. Cowen restated an “outperform” rating and set a $16.00 price objective (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Deutsche Bank reiterated a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a report on Wednesday, September 13th. Morgan Stanley initiated coverage on TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price target on the stock. BidaskClub upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Finally, Jefferies Group reiterated a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $14.50.

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $6.15 on Friday. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30. The firm has a market capitalization of $1,330.00, a P/E ratio of -15.77 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same period in the prior year, the business posted ($0.13) earnings per share. The company’s revenue for the quarter was down 19.7% on a year-over-year basis. analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.

In other news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction on Friday, December 8th. The stock was bought at an average price of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 23.92% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. lifted its position in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after acquiring an additional 818 shares during the period. Amalgamated Bank lifted its position in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after acquiring an additional 1,322 shares during the period. Legal & General Group Plc lifted its position in TherapeuticsMD by 6.5% during the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after acquiring an additional 3,441 shares during the period. The Manufacturers Life Insurance Company lifted its position in TherapeuticsMD by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after acquiring an additional 4,058 shares during the period. Finally, Rhumbline Advisers lifted its position in TherapeuticsMD by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after acquiring an additional 6,232 shares during the period. 73.69% of the stock is owned by institutional investors.

WARNING: “TherapeuticsMD’s (TXMD) “Buy” Rating Reiterated at Noble Financial” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/therapeuticsmd-txmd-receives-buy-rating-from-noble-financial-updated-updated.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply